,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,199 Bay Street,Suite 4000,Toronto,ON,M5L 1A9,Canada,416-854-8884,https://www.fsdpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.",17,"{'maxAge': 1, 'name': 'Mr. Zeeshan  Saeed', 'age': 52, 'title': 'Founder, CEO, Pres & Exec. Co-Chairman', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 375979, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.36,1.36,1.28,1.53,1.36,1.36,1.28,1.53,0.0,1.036719,-3.6585367,1368948,1368948,165775,249470,249470,1.47,1.51,900,1100,58560900,0.618,2.1,1.2528,1.242575,0.0,0.0,USD,53307844,0.0,33146323,39040600,321010,427748,1690761600,1693440000,0.0082,0.23344,0.02684,1.17,0.0097,0.398,3.7688441,1672444800,1703980800,1688083200,-28725148,-0.82,-0.41,1:201,1571184000,-2.134,NCM,EQUITY,HUGE,HUGE,FSD Pharma Inc.,FSD Pharma Inc.,1528464600,America/New_York,EDT,-14400000,1.5,6.0,6.0,6.0,6.0,2.0,buy,1,5670847,0.145,-24982220,417662,1.432,1.557,2.686,-0.50641996,-0.98829,-12926502,-22104824,0.0,0.0,0.0,USD,
1,199 Bay Street,Suite 4000,Toronto,ON,M5L 1A9,Canada,416-854-8884,https://www.fsdpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.",17,"{'maxAge': 1, 'name': 'Mr. Anthony John Durkacz', 'age': 46, 'title': 'Founder & Exec. Co-Chairman', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 375979, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.36,1.36,1.28,1.53,1.36,1.36,1.28,1.53,0.0,1.036719,-3.6585367,1368948,1368948,165775,249470,249470,1.47,1.51,900,1100,58560900,0.618,2.1,1.2528,1.242575,0.0,0.0,USD,53307844,0.0,33146323,39040600,321010,427748,1690761600,1693440000,0.0082,0.23344,0.02684,1.17,0.0097,0.398,3.7688441,1672444800,1703980800,1688083200,-28725148,-0.82,-0.41,1:201,1571184000,-2.134,NCM,EQUITY,HUGE,HUGE,FSD Pharma Inc.,FSD Pharma Inc.,1528464600,America/New_York,EDT,-14400000,1.5,6.0,6.0,6.0,6.0,2.0,buy,1,5670847,0.145,-24982220,417662,1.432,1.557,2.686,-0.50641996,-0.98829,-12926502,-22104824,0.0,0.0,0.0,USD,
2,199 Bay Street,Suite 4000,Toronto,ON,M5L 1A9,Canada,416-854-8884,https://www.fsdpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.",17,"{'maxAge': 1, 'name': 'Mr. Nathan  Coyle CPA', 'age': 41, 'title': 'Chief Financial Officer', 'yearBorn': 1981, 'fiscalYear': 2022, 'totalPay': 191891, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.36,1.36,1.28,1.53,1.36,1.36,1.28,1.53,0.0,1.036719,-3.6585367,1368948,1368948,165775,249470,249470,1.47,1.51,900,1100,58560900,0.618,2.1,1.2528,1.242575,0.0,0.0,USD,53307844,0.0,33146323,39040600,321010,427748,1690761600,1693440000,0.0082,0.23344,0.02684,1.17,0.0097,0.398,3.7688441,1672444800,1703980800,1688083200,-28725148,-0.82,-0.41,1:201,1571184000,-2.134,NCM,EQUITY,HUGE,HUGE,FSD Pharma Inc.,FSD Pharma Inc.,1528464600,America/New_York,EDT,-14400000,1.5,6.0,6.0,6.0,6.0,2.0,buy,1,5670847,0.145,-24982220,417662,1.432,1.557,2.686,-0.50641996,-0.98829,-12926502,-22104824,0.0,0.0,0.0,USD,
3,199 Bay Street,Suite 4000,Toronto,ON,M5L 1A9,Canada,416-854-8884,https://www.fsdpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.",17,"{'maxAge': 1, 'name': 'Mr. Donal  Carroll CPA', 'age': 45, 'title': 'Chief Operating Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 375979, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.36,1.36,1.28,1.53,1.36,1.36,1.28,1.53,0.0,1.036719,-3.6585367,1368948,1368948,165775,249470,249470,1.47,1.51,900,1100,58560900,0.618,2.1,1.2528,1.242575,0.0,0.0,USD,53307844,0.0,33146323,39040600,321010,427748,1690761600,1693440000,0.0082,0.23344,0.02684,1.17,0.0097,0.398,3.7688441,1672444800,1703980800,1688083200,-28725148,-0.82,-0.41,1:201,1571184000,-2.134,NCM,EQUITY,HUGE,HUGE,FSD Pharma Inc.,FSD Pharma Inc.,1528464600,America/New_York,EDT,-14400000,1.5,6.0,6.0,6.0,6.0,2.0,buy,1,5670847,0.145,-24982220,417662,1.432,1.557,2.686,-0.50641996,-0.98829,-12926502,-22104824,0.0,0.0,0.0,USD,
4,199 Bay Street,Suite 4000,Toronto,ON,M5L 1A9,Canada,416-854-8884,https://www.fsdpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.",17,"{'maxAge': 1, 'name': 'Dr. Lakshmi P. Kotra BPHARM, Ph.D.', 'age': 51, 'title': 'CEO of Lucid & Director', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 331510, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.36,1.36,1.28,1.53,1.36,1.36,1.28,1.53,0.0,1.036719,-3.6585367,1368948,1368948,165775,249470,249470,1.47,1.51,900,1100,58560900,0.618,2.1,1.2528,1.242575,0.0,0.0,USD,53307844,0.0,33146323,39040600,321010,427748,1690761600,1693440000,0.0082,0.23344,0.02684,1.17,0.0097,0.398,3.7688441,1672444800,1703980800,1688083200,-28725148,-0.82,-0.41,1:201,1571184000,-2.134,NCM,EQUITY,HUGE,HUGE,FSD Pharma Inc.,FSD Pharma Inc.,1528464600,America/New_York,EDT,-14400000,1.5,6.0,6.0,6.0,6.0,2.0,buy,1,5670847,0.145,-24982220,417662,1.432,1.557,2.686,-0.50641996,-0.98829,-12926502,-22104824,0.0,0.0,0.0,USD,
5,199 Bay Street,Suite 4000,Toronto,ON,M5L 1A9,Canada,416-854-8884,https://www.fsdpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.",17,"{'maxAge': 1, 'name': 'Dr. Andrzej  Chruscinski M.D., Ph.D.', 'title': 'VP of Clinical & Scientific Affairs of Lucid', 'fiscalYear': 2022, 'totalPay': 110304, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.36,1.36,1.28,1.53,1.36,1.36,1.28,1.53,0.0,1.036719,-3.6585367,1368948,1368948,165775,249470,249470,1.47,1.51,900,1100,58560900,0.618,2.1,1.2528,1.242575,0.0,0.0,USD,53307844,0.0,33146323,39040600,321010,427748,1690761600,1693440000,0.0082,0.23344,0.02684,1.17,0.0097,0.398,3.7688441,1672444800,1703980800,1688083200,-28725148,-0.82,-0.41,1:201,1571184000,-2.134,NCM,EQUITY,HUGE,HUGE,FSD Pharma Inc.,FSD Pharma Inc.,1528464600,America/New_York,EDT,-14400000,1.5,6.0,6.0,6.0,6.0,2.0,buy,1,5670847,0.145,-24982220,417662,1.432,1.557,2.686,-0.50641996,-0.98829,-12926502,-22104824,0.0,0.0,0.0,USD,
6,199 Bay Street,Suite 4000,Toronto,ON,M5L 1A9,Canada,416-854-8884,https://www.fsdpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.",17,"{'maxAge': 1, 'name': 'Mr. Kevin  Cassidy', 'title': 'VP of Quality-Lucid', 'fiscalYear': 2022, 'totalPay': 144822, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.36,1.36,1.28,1.53,1.36,1.36,1.28,1.53,0.0,1.036719,-3.6585367,1368948,1368948,165775,249470,249470,1.47,1.51,900,1100,58560900,0.618,2.1,1.2528,1.242575,0.0,0.0,USD,53307844,0.0,33146323,39040600,321010,427748,1690761600,1693440000,0.0082,0.23344,0.02684,1.17,0.0097,0.398,3.7688441,1672444800,1703980800,1688083200,-28725148,-0.82,-0.41,1:201,1571184000,-2.134,NCM,EQUITY,HUGE,HUGE,FSD Pharma Inc.,FSD Pharma Inc.,1528464600,America/New_York,EDT,-14400000,1.5,6.0,6.0,6.0,6.0,2.0,buy,1,5670847,0.145,-24982220,417662,1.432,1.557,2.686,-0.50641996,-0.98829,-12926502,-22104824,0.0,0.0,0.0,USD,
7,199 Bay Street,Suite 4000,Toronto,ON,M5L 1A9,Canada,416-854-8884,https://www.fsdpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.",17,"{'maxAge': 1, 'name': 'Ms. Maryann  Adesso', 'title': 'Corp. Sec.', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.36,1.36,1.28,1.53,1.36,1.36,1.28,1.53,0.0,1.036719,-3.6585367,1368948,1368948,165775,249470,249470,1.47,1.51,900,1100,58560900,0.618,2.1,1.2528,1.242575,0.0,0.0,USD,53307844,0.0,33146323,39040600,321010,427748,1690761600,1693440000,0.0082,0.23344,0.02684,1.17,0.0097,0.398,3.7688441,1672444800,1703980800,1688083200,-28725148,-0.82,-0.41,1:201,1571184000,-2.134,NCM,EQUITY,HUGE,HUGE,FSD Pharma Inc.,FSD Pharma Inc.,1528464600,America/New_York,EDT,-14400000,1.5,6.0,6.0,6.0,6.0,2.0,buy,1,5670847,0.145,-24982220,417662,1.432,1.557,2.686,-0.50641996,-0.98829,-12926502,-22104824,0.0,0.0,0.0,USD,
8,199 Bay Street,Suite 4000,Toronto,ON,M5L 1A9,Canada,416-854-8884,https://www.fsdpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.",17,"{'maxAge': 1, 'name': 'Randell  Mack', 'title': 'Pres of FSD BioSciences', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.36,1.36,1.28,1.53,1.36,1.36,1.28,1.53,0.0,1.036719,-3.6585367,1368948,1368948,165775,249470,249470,1.47,1.51,900,1100,58560900,0.618,2.1,1.2528,1.242575,0.0,0.0,USD,53307844,0.0,33146323,39040600,321010,427748,1690761600,1693440000,0.0082,0.23344,0.02684,1.17,0.0097,0.398,3.7688441,1672444800,1703980800,1688083200,-28725148,-0.82,-0.41,1:201,1571184000,-2.134,NCM,EQUITY,HUGE,HUGE,FSD Pharma Inc.,FSD Pharma Inc.,1528464600,America/New_York,EDT,-14400000,1.5,6.0,6.0,6.0,6.0,2.0,buy,1,5670847,0.145,-24982220,417662,1.432,1.557,2.686,-0.50641996,-0.98829,-12926502,-22104824,0.0,0.0,0.0,USD,
